UBS Maintains a 'Neutral' on Clearwire (CLWR); Oct. 7 Could Be A Negative Catalyst
Get Alerts CLWR Hot Sheet
Price: $4.99 --0%
Rating Summary:
2 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
2 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
UBS maintains a 'Neutral' on Clearwire (NASDAQ: CLWR) price target lowered by $1 to $3.
UBS analyst says, "CLWR shares remain under pressure given Sprint’s apparent unwillingness to take on CLWR debt and its potential alternatives for 4G. We expect Sprint to announce an organic LTE build, along with the iPhone and faster progress on Network Vision, at its Oct. 7 analyst meeting, which could be a negative catalyst for CLWR." (UBS lowers FY11 EPS estimate from (1.90) to (1.96) and FY12 from (1.19) to (1.23))
For more ratings news on Clearwire click here and for the rating history of Clearwire click here.
Shares of Clearwire closed at $2.73 yesterday.
UBS analyst says, "CLWR shares remain under pressure given Sprint’s apparent unwillingness to take on CLWR debt and its potential alternatives for 4G. We expect Sprint to announce an organic LTE build, along with the iPhone and faster progress on Network Vision, at its Oct. 7 analyst meeting, which could be a negative catalyst for CLWR." (UBS lowers FY11 EPS estimate from (1.90) to (1.96) and FY12 from (1.19) to (1.23))
For more ratings news on Clearwire click here and for the rating history of Clearwire click here.
Shares of Clearwire closed at $2.73 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
- EQT Corp. (EQT) PT Lowered to $46 at Wolfe Research
- Boston Scientific (BSX) PT Raised to $83 at Stifel
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!